Senior Scientist, Immunotherapy, Pre-clinical Development, Elevatebio
Speaker
Abstract
In this webinar, Dr. Sandra Milasta, Senior Scientist of Elevatebio will discuss how metabolic pathways maintain lymphocyte survival, drive memory vs. effector function, and the implications of these findings on the development of next generation T cell-based therapies. There has been growing interest in the field of immunotherapy to understand if we can shape the T cell response by targeting T cell metabolism.
You May Also Like
MAR 26, 2024 | 7:00 PM
C.E. CREDITS
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
MAR 26, 2024 | 8:00 AM
C.E. CREDITS
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
DEC 12, 2023 15:00 CET
C.E. CREDITS
The implementation of the new CE-In Vitro Diagnostics Regulation (IVDR) involves challenges faced by labs that are working within the diagnostic environment. The aim of this event is to get...
MAR 26, 2024 | 11:00 AM
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
NOV 29, 2023 | 9:00 AM
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
APR 02, 2024 | 8:00 AM
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
Loading Comments...
Finish Registering
-
APR 30, 2024Immuno-Oncology Virtual Event Series 2024 -
MAY 07, 20243rd International Biosecurity Virtual Symposium
-
MAY 23, 2024For the Love of Digital PCR 2024
- See More
-
APR 26, 2024
- See More
